


The World's First NIR (Near Infrared II Region)
Fluorescence Detection Technology from
Stanford University U.S.A.



Ultra-sensitive Diagnostic Assays!




NIR-1000 FIA

Fluorescent Nanospheres in NIR (Near Infrared) window

- Ultra-high Sensitivity and excellent precision.
- Fast and Flexible, result in short time.
- Intelligent QR code management.
- Real-time data transmission, compatible with LIS/HIS.
- Storage 10,000 results.
- Large touch screen LCD display.

NIR Infrared Fluorescence POCT (NIR-LF™ Platform)

Perfect Combination of Ultra-bright Infrared Fluorescent Molecules and Nano-biotechnology




A New Generation of Near Infrared II Region Fluorescent Nanospheres

- The quantum yield of the fluorescent nanospheres exceeds 30% with emission peak in near infrared II region (1000-1700nm).
- Ultra high sensitivity with over 400nm of Stokes shift.
- Infrared fluorescence detection reduces the interference of self-fluorescence in the detection samples and increases penetration depth of signals.
- Super strong anti-interference ability for high blood lipids, jaundice and hemolytic samples.
- Excluding autofluorescence interference from samples.

Detecting wavelength of chemiluminescence and traditional immunofluorescence technologies

Unaffected by the absorption, autofluorescence, and light scattering of biological samples



NIR-1000 FIA

Fluorescent Nanospheres in NIR (Near Infrared) window

	Product item	Specimen	Reaction Time	Measure Range	Clinical Range	Intended Use
Cardiac	cTnl	WB/Serum/Plasma	12min.	0.1-40ng/ml	<0.3ng/ml	Several heart diseases including myocardial infarction and heart failure.
	Myo	WB/Serum/Plasma	12min.	5-400ng/ml	<58ng/ml	Acute myocardial infarction (AMI) in early stage.
	CK-MB	WB/Serum/Plasma	12min.	1-200ng/ml	<5ng/ml	Acute myocardial infarction (AMI) in early stage.
	NT-proBNP	WB/Serum/Plasma	10min.	20-35000pg/ml	Under 75: 0~347pg/mL Over 75: 0~449pg/mL	Heart failure.
	D-Dimer	WB/Plasma	10min.	40-10000ng/ml	<500ng/ml	Disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, cerebral infarction, etc.
	ST2	WB/Serum/Plasma	10min.	10-400ng/ml	<35ng/ml	Heart failure.
Inflammation	CRP / hs-CRP	WB/Serum/Plasma	3min.	0.5-200mg/L	CRP<10mg/L hs-CRP<1mg/L	Nonspecificity inflammatory marker.
	SAA	WB/Serum	5min.	1-200mg/L	<10mg/L	Inflammation & infection.
	PCT	WB/Serum/Plasma	10min.	0.2-100ng/ml	<0.5ng/ml	Sepsis.
	IL-6	WB/Serum/Plasma	10min.	5-4000pg/ml	10pg/ml	Diabetes, rheumatoid arthritis, etc.
Thyroid Hormone	TSH	WB/Serum/Plasma	15min.	0.3-100mU/L	0.3-4.2mU/L	Hyperthyroidism and hypothyroidism.
	TT3	WB/Serum/Plasma	15min.	0.5-10nmol/L	1.23-3.07nmol/L	Thyroid dysfunction.
	TT4	WB/Serum/Plasma	15min.	5-300nmol/L	66-181nmol/L	Thyroid dysfunction.
	FT3	WB/Serum/Plasma	15min.	1-50pmol/L	3.1-6.8pmol/L	Thyroid dysfunction.
	FT4	WB/Serum/Plasma	15min.	5-100pmol/L	12-22pmol/L	Thyroid dysfunction.
Tumor Marker	AFP	WB/Serum/Plasma	10min.	2.5-200ng/ml	<20ng/ml	Pregnancy cancer.
	CEA	WB/Serum/Plasma	10min.	1-200ng/ml	<5ng/ml	Colon cancer, colorectal cancer, etc.
	PG II	WB/Serum/Plasma	10min.	1-100ug/L	PGI/PGII>3.0	Gastric abnormalities.
	PG I	WB/Serum/Plasma	10min.	2.5-200ug/L	>70ng/ml	Gastric abnormalities.
	TPSA	WB/Serum/Plasma	10min.	0.5-40ng/ml	<4ng/ml	Prostate cancer.
	FPSA	WB/Serum/Plasma	10min.	0.1-10ng/ml	<1ng/ml	Prostate cancer.
	CA12-5	WB/Serum/Plasma	10min.	20-500U/ml	<35U/ml	Ovarian cancer.
	CA15-3	WB/Serum/Plasma	10min.	10-400U/ml	< 25 U/mL	Breast cancer.
	CA19-9	WB/Serum/Plasma	10min.	10-400U/ml	< 27 U/mL	Pancreatic cancer.
Fertility	β-HCG	WB/Serum/Plasma	10min.	2-100000mIU/ml	<5 mIU/mL	Early pregnancy.
	AMH	WB/Serum/Plasma	10min.	0.1-16ng/ml	Male: 20-60 years old, 0.92-13.89 ng/mL Female: • 20-29 years old, 0.88-10.35 ng/mL • 30-39 years old, 0.31-7.86 ng/mL • 40-50 years old, <5.07 ng/mL	Ovarian reserve level.
	LH	WB/Serum/Plasma	15min.	1-100mIU/ml	Male: 1.81-8.16 mIU/mL; Female: Follicular phase : 2.95-13.65 mIU/mL Ovulation phase: 13.65-95.75 mIU/mL Luteal phase: 1.25-11.00 mIU/mL Menopause phase: 8.74-55.00 mIU/mL	Reproductive dysfunction.

	Product item	Specimen	Reaction Time	Measure Range	Clinical Range	Intended Use
Fertility	FSH	WB/Serum/Plasma	15min.	1-100mIU/ml	Male: 1.50-12.40 mIU/mL Female: Follicular phase : 4.46-12.43 mIU/mL Ovulation phase: 4.88-20.96 mIU/mL Luteal phase: 1.95-8.04 mIU/mL Menopause phase: 20.00-98.62 mIU/mL	Reproductive system.
	Testosterone	WB/Serum/Plasma	15min.	0.2-15ng/ml	Male: 20-49 years old, 1.91-8.41 ng/mL >50 years old, 1.61-8.01 ng/mL Female: 20-49 years old, <0.80ng/mL >50 years old, <0.71 ng/mL	Sexual hormone disturbance and hypogonadism.
	Progesterone	WB/Serum/Plasma	15min.	1.4-60ng/ml	Male: 0-1.5ng/mL Female: Follicular phase : 0-1.9ng/mL Ovulation phase: 0-12ng/mL Luteal phase: 1.7-28.7ng/mL Menopause phase: 0-1.4ng/mL Pregnancy: 11-60ng/mL	Pregnancy progesterone.
	PRL	WB/Serum/Plasma	15min.	1-200ng/ml	Male: 3.45-17.42 ng/mL Female (non-pregnant): 4.60-25.07 ng/mL	Breastfeeding & abnormal lactation.
	E2	WB/Serum/Plasma	15min.	9-3000pg/ml	Male: <85 pg/mL Female: Follicular Phase: 12-262 pg/mL Ovulation: 40-396 pg/mL Luteal Phase: 21-381 pg/mL Menopause: <190 pg/mL Pregnancy: >145 pg/mL	Ovarian vitality.

	Product item	Specimen	Reaction Time	Measure Range	Clinical Range	Intended Use
Gastrointestinal	FOB+TRF	Fecal Specimens	10min.	Qualitative	Qualitative	Gastrointestinal hemorrhage.
Infection	Covid-19 Antigen	Nasal swab, throat swab or nasal wash/aspirate specimens	15min.	Qualitative	Qualitative	Respiratory tract.
	Covid-19 Ab IgG/IgM	WB/Serum/Plasma	15min.	Qualitative	Qualitative	Respiratory tract.
	FluA Antigen	Nasal swab, throat swab or nasal wash/aspirate specimens	15min.	Qualitative	Qualitative	Respiratory tract.
	FluB Antigen	Nasal swab, throat swab or nasal wash/aspirate specimens	15min.	Qualitative	Qualitative	Respiratory tract.
	HPAntigen	Fecal specimens	15min.	0.05-100ng/mL	<0.1ng/mL	Pylori infection.
	HP IgG	WB/Serum/Plasma	15min.	3-80ng/mL	<5ng/mL	Pylori infection.
Renal Injury	CysC	WB/Serum/Plasma	5min.	0.4-9mg/L	0.5-1.1mg/L	Renal function.
	NGAL	Urine	10min.	10-1500ng/mL	<132ng/mL	Acute kidney injury.
	MAU	Urine	10min.	5-300mg/l	<20mg/l	Renal function.
Diabetes	HbA1c	WB	10min.	4%-14%	4%-6%	Diabetes.
	Insulin	WB/Serum/Plasma	15min.	1-200 μU/mL	5-20μU/mL	Diabetes.
	C-peptide	WB/Serum/Plasma	15min.	0.1-16ng/mL	0.33-3.76ng/mL	Diabetes.
Brain diseases	S100β	WB/Serum/Plasma	10min.	0.05-10ng/ml	<0.2ng/ml	Cerebral infarction, cerebral injury.
Nutritional metabolism	FERR	WB/Serum/Plasma	5min.	10-500ng/mL	Male: 24ng/mL~335ng/mL Female: 11ng/mL~307ng/mL	Iron metabolism related diseases, such as hemochromatosis and iron deficiency anemia.
	VD	WB/Serum/Plasma	15min.	30-120ng/mL	30-70ng/mL	Osteoporosis.
	VB12	WB/Serum/Plasma	15min.	50-2000pg/mL	200-900pg/mL	VB12 deficiency.
Auto-immune	Total IgE	WB/Serum/Plasma	10min.	0.05-10mg/L	0.1-0.9mg/L	Allergy, rickets.

WWHS BIOTECH, Inc.

Rm 505, 1st Building, Shenzhen Biomedicine
Innovation Industrial Park, No. 14th, Jinhui Road,
East Jinxiu Road, Kengzi Street, Pingshan District,
Shenzhen, Guangdong, P.R. China

TEL: +86 755-8423 5529; +86 15989858521

Email: Sales@wwhsbio.com

Web: www.wwhsbio.com






01 Bring the kits to room temperature



02 Insert ID chip
(reading parameter)



03 Take out the
test card



04 Mixed sample to
the test card



05 Insert the card and
start to read

NIR-1000 Dry Fluoroimmunoassay Analyzer

NMPA Reg.NO. 20192221229



Unique Wavelength

Unique near infrared excitation and near infrared II region detection.
Infrared laser excitation

Diversity Compatible

Plasma, whole blood, peripheral blood, urine, saliva, feces and other samples

High Precision

CV $\leq$ 2.0%; Accuracy: $\leq$ $\pm$ 3.0%; stability: $\leq$ $\pm$ 3.0%

Fast and Flexible

Finished detection within 8 seconds

Intelligence

QR code management.
Connection with LIS/HIS system by cable/wireless

Information Storage

10000 patient sample testing information storage capacity

Humanization Design

Full screen operation, simple and convenient.
Comfortable customer experience